Chloroquine neuromyotoxicity. Clinical and pathologic perspective

      This paper is only available as a PDF. To read, Please Download here.


      Six cases of toxic myopathy and/or neuropathy with chloroquine and/or hydroxychloroquine therapy are described. Two patients had unique clinical and pathologic evidence of cardiomyopathy secondary to chloroquine or hydroxychloroquine therapy. One patient had polyneuropathy secondary to chloroquine toxicity. This may be the first documentation of several features of chloroquine/hydroxychloroquine toxicity: (1) morphologic changes in human peripheral nerve in chloroquine toxicity; (2) chloroquine/hydroxychloroquine cardiomyopathy diagnosed by endomyocardial biopsy; and (3) hydroxychloroquine myotoxicity. Chloroquine is a neuromyotoxin that affects nerves and cardiac and skeletal muscles. Discontinuation of chloroquine and hydroxychloroquine resulted in marked improvement in most cases. The reversibility of the symptoms emphasizes the importance of recognizing potential signs of nerve, muscle, and cardiac toxicity in patients being treated with chloroquine or hydroxychloroquine.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Whisnant JP
        • Espinosa RF
        • Kierland RR
        • Lambert EH
        Chloroquine neuromyopathy.
        in: 5th ed. Proc Mayo Clin. 38. 1963: 501-513
        • Eadie MJ
        • Ferrier TM
        Chloroquine myopathy.
        J Neurol Neurosurg Psychiatry. 1966; 29: 331-337
        • Rewcastle NB
        • Humphrey JG
        Vacuolar myopathy: clinical, histochemical, and microscopic study.
        Arch Neurol. 1965; 12: 570-582
        • Mastaglia FL
        • Papadimitriou JM
        • Dawkins RL
        • Beveridge BL
        Vacuolar myopathy associated with chloroquine, lupus erythematosus, and thymoma.
        J Neurol Sci. 1977; 34: 315-328
        • Neville HE
        • Maunder-Sewry CA
        • McDougall J
        • Sewell JR
        • Dubowitz V
        Chloroquine-induced cytosomes with curvilinear profiles in muscle.
        Muscle Nerve. 1979; 2: 376-381
        • Gerard JM
        • Stoupel N
        • Collier A
        • et al.
        A morphologic study of neuromyopathy caused by prolonged chloroquine treatment.
        Eur Neurol. 1973; 9: 363-379
        • Scherbel AL
        Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: historic and therapeutic perspectives.
        Am J Med. 1983; 75: 1-4
        • McChesney EW
        Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.
        Am J Med. 1983; 75: 11-18
        • Fedorko ME
        • Hirsch JG
        • Cohn ZA
        Autophagic vacuoles produced in vitro—I. Studies in cultured macrophages exposed to chloroquine.
        J Cell Biol. 1968; 38: 377-391
        • MacDonald RD
        • Engel AG
        Experimental chloroquine myopathy.
        J Neuropathol Exp Neurol. 1970; 29: 479-499
        • Engel AG
        Evolution and content of vacuoles in primary hypokalemic periodic paralysis.
        Mayo Clin Proc. 1970; 44: 774-814
        • Schnalbrach H
        The early changes in experimental myopathy induced by chloroquine and chlorophentermine.
        J Neuropathol Exp Neurol. 1980; 39: 65-80
        • Dyken P
        • Krawiecki N
        Neurodegenerative disease of infancy and childhood.
        Ann Neurol. 1983; 13: 351-354
        • Goodman LS
        • Gilman A
        The pharmacological basis of therapeutics.
        in: 5th ed. Macmillan, New York1975: 1046-1049
        • MacKenzie AH
        Pharmacologic actions of 4-aminoquinoline compounds.
        Am J Med. 1983; 75: 5-10
        • McChesney EW
        • Bank Jr, WF
        • Sullivan DJ
        Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats.
        Toxicol Appl Pharmacol. 1965; 7: 625-626
        • Ratliff NB
        • Estes ML
        • Myles J
        • Shirey E
        • McMahon J
        The diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy.
        N Engl J Med. 1987; 316: 191-193
        • Nelson AA
        • Fitzhugh OG
        Chloroquine (SN-7618); pathologic changes observed in rats which for two years had been fed various proportions.
        Arch Pathol. 1948; 45: 454-462
        • Smith B
        • O'Grady F
        Experimental chloroquine myopathy.
        J Neurol Neurosurg Psychiatry. 1966; 29: 255-258
        • Aguayo AJ
        • Hudson P
        Observations on the short-term effects of chloroquine on skeletal muscle: an experimental study in rabbits.
        J Neurol Sci. 1970; 11: 301-325
        • Hughes T
        • Esiri M
        • Oxbury JM
        • Whitty CWM
        Chloroquine myopathy.
        Q J Med. 1971; 157: 85-93
        • Stauber WT
        • Hedge AM
        • Trout JJ
        • Schottelius BA
        Inhibition of lysosomal function in red and white skeletal muscles by chloroquine.
        Exp Neurol. 1981; 71: 295-306
        • Trout JT
        • Stauber WT
        • Schottelius BA
        Increased autophagy in chloroquine treated tonic and phasic muscles: an alternative view.
        Tissue Cell. 1981; 13: 393-401
        • Klinghardt GW
        Experimentelle Schadiyunen von Nerven-system and muskulature durch chlorochin.
        Acta Neuropathol (Berl). 1974; 28: 117-141
        • Blomberg LH
        Dystrophica myotonica probably caused by chloroquine.
        Acta Neurol Scand. 1965; 41 (part II): 647-651
        • Begg TB
        • Simpson JA
        Chloroquine neuromyopathy (letter).
        Br Med J. 1964; 1: 770
        • Kakulas BA
        Toxic and drug induced myopathies.
        in: Mastaglia FI Walton J Skeletal muscle pathology. Churchill Livingstone, London1982: 409-426
        • Banker BQ
        • Engle AG
        The polymyositis and dermatomyositis syndromes.
        in: Engle AG Banker BQ Myology. McGraw-Hill, New York1986: 1395-1398
        • Pearson CM
        • Yamazaki JN
        Vacuolar myopathy systemic lupus erythematosus.
        Am J Clin Pathol. 1958; 29: 455-463
        • Rynes RI
        Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment.
        Am J Med. 1983; 75: 35-40